74 related articles for article (PubMed ID: 16154353)
1. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Maindrault-Goebel F; André T; Tournigand C; Louvet C; Perez-Staub N; Zeghib N; De Gramont A
Eur J Cancer; 2005 Oct; 41(15):2262-7. PubMed ID: 16154353
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity reaction to nedaplatin: A case report and literature review.
Gan K; Ma D
Medicine (Baltimore); 2023 Dec; 102(50):e36690. PubMed ID: 38115255
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
[TBL] [Abstract][Full Text] [Related]
4. High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy.
Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Feng A; Wang X; Cao G; Xu L; Chen H; Liu P; Xu H; Gao Q; Yang R; Zhu X
Int Immunopharmacol; 2024 Mar; 130():111767. PubMed ID: 38430809
[TBL] [Abstract][Full Text] [Related]
5. [Retrospective analysis of perioperative anaphylactic shock induced by cefuroxime].
Chen MF; Zhang JF; Ren XL; Liu Y; Huang L
Zhonghua Nei Ke Za Zhi; 2024 Apr; 63(4):406-411. PubMed ID: 38561287
[TBL] [Abstract][Full Text] [Related]
6. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Zhao Y; An X; Xiang XJ; Feng F; Wang FH; Wang ZQ; Xu RH; He YJ; Li YH
Chin J Cancer; 2010 Jan; 29(1):102-5. PubMed ID: 20038320
[TBL] [Abstract][Full Text] [Related]
8. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
[TBL] [Abstract][Full Text] [Related]
9. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.
Galateanu B; Pușcașu AI; Tircol SA; Tanase BC; Hudita A; Negrei C; Burcea-Dragomiroiu GT; Negreanu L; Vacaroiu IA; Ginghină O
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835299
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review.
Barbin F; Ghidini M; Panichi A; Tomasello G; Bareggi C; Galassi B; Denaro N; Ruatta F; Cauchi C; Rossino MG; Garrone O
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552030
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.
Song Q; Cai Y; Guo K; Li M; Yu Z; Tai Q; Zhao Y; Zhu X; Zhang C
Am J Transl Res; 2022; 14(4):2461-2468. PubMed ID: 35559366
[TBL] [Abstract][Full Text] [Related]
12. Severe anaphylaxis caused by intravenous anti-cancer drugs.
Horita N; Miyagi E; Mizushima T; Hagihara M; Hata C; Hattori Y; Hayashi N; Irie K; Ishikawa H; Kawabata Y; Kitani Y; Kobayashi N; Kobayashi N; Kurita Y; Miyake Y; Miyake K; Oguri S; Ota I; Shimizu A; Takeuchi M; Yamada A; Yamamoto K; Yukawa N; Masuda M; Oridate N; Ichikawa Y; Kaneko T
Cancer Med; 2021 Oct; 10(20):7174-7183. PubMed ID: 34505396
[TBL] [Abstract][Full Text] [Related]
13. Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.
Caiado J; Castells MC
Curr Allergy Asthma Rep; 2021 Jul; 21(6):37. PubMed ID: 34232411
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.
Stack A; Khanal R; Denlinger CS
Clin Colorectal Cancer; 2021 Mar; 20(1):e1-e4. PubMed ID: 33012678
[TBL] [Abstract][Full Text] [Related]
15. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.
Castells M
Front Immunol; 2017; 8():1472. PubMed ID: 29163536
[TBL] [Abstract][Full Text] [Related]
16. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.
Bupathi M; Hajjar J; Bean S; Fu S; Hong D; Karp D; Stephen B; Hess K; Meric-Bernstam F; Naing A
Invest New Drugs; 2017 Feb; 35(1):59-67. PubMed ID: 27687047
[TBL] [Abstract][Full Text] [Related]
17. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
[TBL] [Abstract][Full Text] [Related]
18. Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.
Caiado J; Castells M
Curr Allergy Asthma Rep; 2015 Apr; 15(4):15. PubMed ID: 26130472
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.
Caiado J; Picard M
Curr Allergy Asthma Rep; 2014 Aug; 14(8):451. PubMed ID: 24951237
[TBL] [Abstract][Full Text] [Related]
20. Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
Seki K; Tsuduki Y; Ioroi T; Yamane M; Yamauchi H; Shiraishi Y; Ogawa T; Nakata I; Nishiguchi K; Matsubayashi T; Takakubo Y; Yamamori M; Kuwahara A; Okamura N; Sakaeda T
Int J Med Sci; 2014; 11(6):641-5. PubMed ID: 24782655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
